Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 3/20 | 0.33 |
| ▸ | ADH1A | P07327 | 3/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923554 | 0.98 | EPHX1 (0.39) | EPHX1DPP4ADH1CADH1AHSD11B1 | |
| SCHEMBL13494081 | 0.86 | F2 (0.38) | EPHX1HSD11B1GAA | |
| SCHEMBL3763763 | 0.84 | EPHX1 (0.37) | EPHX1DPP4ADH1CADH1AHDAC6 | |
| SCHEMBL27510109 | 0.83 | EPHX1 (0.39) | EPHX1DPP4HSD11B1GAA | |
| Formic Acid SCHEMBL27813327 | 0.82 | CCR5 (0.39) | DPP4ADH1CADH1AHSD11B1 | |
| SCHEMBL13769592 | 0.80 | EPHX1 (0.37) | EPHX1DPP4BTKHSD11B1GAA | |
| SCHEMBL3714007 | 0.80 | EPHX1 (0.34) | EPHX1DPP4BTKHSD11B1GAA | |
| SCHEMBL10323856 | 0.80 | CA14 (0.34) | EPHX1DPP4BTKHSD11B1GAA | |
| SCHEMBL992260 | 0.80 | — | — | |
| SCHEMBL16106366 | 0.80 | HSD11B1 (0.37) | EPHX1DPP4BTKHSD11B1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-08-28 | — | — | US | disclosed |
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095058-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2008-08-07 | — | — | WO | disclosed |
| US-5935932-A | Bradykinin antagonists containing pentafluorophenylalanine | UNIVERSITY TECHNOLOGY CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | GLS2, SLC10A1, UGT1A1 | EPHX1 1321/4885DPP4 456/4885ADH1C 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.